Cardiac responses in paediatric Pompe disease in the ADVANCE patient cohort
| Autor: | David Kronn, Kristina An Haack, James B. Gibson, Si Houn Hahn, Meredith C. Foster, Raymond Y. Wang, Pranoot Tanpaiboon, David W. Stockton, Priya S. Kishnani, Barry J. Byrne, Steven D. Colan, Loren D.M. Pena, Judith Johnson, Susan Sparks, Nancy D. Leslie, Richard Hillman |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Genotype Cardiomyopathy Cardiomegaly Cohort Studies Internal medicine medicine Humans Enzyme Replacement Therapy Alglucosidase alfa medicine.diagnostic_test business.industry Glycogen Storage Disease Type II General Medicine Enzyme replacement therapy medicine.disease Confidence interval Blood pressure Phenotype Concomitant Pediatrics Perinatology and Child Health Cohort Cardiology Cardiology and Cardiovascular Medicine business Electrocardiography medicine.drug |
| Zdroj: | Cardiology in the young. 32(3) |
| ISSN: | 1467-1107 |
| Popis: | Pompe disease results from lysosomal acid α-glucosidase deficiency, which leads to cardiomyopathy in all infantile-onset and occasional late-onset patients. Cardiac assessment is important for its diagnosis and management. This article presents unpublished cardiac findings, concomitant medications, and cardiac efficacy and safety outcomes from the ADVANCE study; trajectories of patients with abnormal left ventricular mass z score at enrolment; and post hoc analyses of on-treatment left ventricular mass and systolic blood pressure z scores by disease phenotype, GAA genotype, and “fraction of life” (defined as the fraction of life on pre-study 160 L production-scale alglucosidase alfa). ADVANCE evaluated 52 weeks’ treatment with 4000 L production-scale alglucosidase alfa in ≥1-year-old United States of America patients with Pompe disease previously receiving 160 L production-scale alglucosidase alfa. M-mode echocardiography and 12-lead electrocardiography were performed at enrolment and Week 52. Sixty-seven patients had complete left ventricular mass z scores, decreasing at Week 52 (infantile-onset patients, change −0.8 ± 1.83; 95% confidence interval −1.3 to −0.2; all patients, change −0.5 ± 1.71; 95% confidence interval −1.0 to −0.1). Patients with “fraction of life” Trial registry: ClinicalTrials.gov Identifier: NCT01526785 https://clinicaltrials.gov/ct2/show/NCT01526785.Social Media Statement: Post hoc analyses of the ADVANCE study cohort of 113 children support ongoing cardiac monitoring and concomitant management of children with Pompe disease on long-term alglucosidase alfa to functionally improve cardiomyopathy and/or dysrhythmia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|